Wim Timens

39.3k citations

458 papers · 20.3k indexed · 3 hit papers · h-index 68

Impact in

Infectious Diseases top 0.2%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
Pulmonary and Respiratory Medicine top 0.1%
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Neonatal Respiratory Health Research
- Respiratory Support and Mechanisms

Papers in

Pulmonary and Respiratory Medicine 256
- Chronic Obstructive Pulmonary Disease (COPD) Research 110
- Neonatal Respiratory Health Research 62
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis 37
- Lung Cancer Treatments and Mutations 31
- Respiratory and Cough-Related Research 26
Physiology 127
- Asthma and respiratory diseases 104

Co-authors: Harry van Goor Dirkje S. Postma G. Navis Inge Hamming A. Titia Lely James C. Hogg Machteld N. Hylkema Corry‐Anke Brandsma
Journals: European Respiratory Journal (32 papers)PLoS ONE (20 papers)Respiratory Research (19 papers)American Journal of Physiology-Lung Cellular and Molecular Physiology (15 papers)Thorax (14 papers)
Partner nations: Netherlands United States Canada

In The Last Decade

Wim Timens

443 papers receiving 19.9k citations

Hit Papers

align trajectories log scale

Angiotensin‐converting enzyme 2 (ACE2), SARS‐CoV‐2 and the pathophysiology of coronavirus disease 2019 (COVID‐19) 2020 · 764 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2020 The Journal of Pathology
2008 Annual Review of Pathology Mechanisms of Disease
2004 The Journal of Pathology

Peers

Countries citing papers authored by Wim Timens

Since Specialization

Citations

This map shows the geographic impact of Wim Timens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wim Timens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wim Timens more than expected).

Fields of papers citing papers by Wim Timens

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wim Timens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wim Timens. The network helps show where Wim Timens may publish in the future.

Co-authors

The 25 scholars most cited alongside Wim Timens, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Wim Timens Line = papers co-authored together Wim Timens links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Effect of age, COPD severity, and cigarette smoke exposure on bronchial epithelial barrier function American Journal of Physiology-Lung Cellular and Molecular Physiology ·Edith Bourret-Courchesne, Tillie‐Louise Hackett, Qing Chen, Chen Xi Yang, Z. Chen, Pía Uribe, 加織山西, Tessa Kole, Alen Faiz, Geethu S. Kumar, Dirk‐Jan Slebos, Karin Klooster, Wim Timens, Maarten van den Berge, Corry‐Anke Brandsma, Irene H. Heijink	2025	5
2	Osteoprotegerin is an Early Marker of the Fibrotic Process and of Antifibrotic Treatment Responses in Ex Vivo Lung Fibrosis Lung ·Ian Alvarado-Vélez, B. Emonts, Carian E. Boorsma, Gloria A. Gaskin, Mitchel J. R. Ruigrok, Peter Heukels, Wim Timens, Marina H. de Jager, Wouter L.J. Hinrichs, Peter Olinga, Barbro N. Melgert	2024	2
3	Age-associated differences in the human lung extracellular matrix American Journal of Physiology-Lung Cellular and Molecular Physiology ·洋藤沢, Maaike de Vries, Theo Borghuis, Wim Timens, Don D. Sin, David C. Nickle, Philippe Joubert, Péter Horvatovich, György Marko‐Varga, Jacob J. Teske, Judith M. Vonk, Reinoud Gosens, Y. S. Prakash, Janette K. Burgess, Corry‐Anke Brandsma	2023	28
4	Establishing an economical and widely accessible donation after circulatory death animal abattoir model for lung research using ex vivo lung perfusion Artificial Organs ·勝也平井, Fengzi Yao, Sandy Cassady, Roland F. Hoffmann, Raul Ruiz Mendoza, Caroline Van De Wauwer, Wim Timens, Toshihiro Okamoto, Erik A.M. Verschuuren, Henri G. D. Leuvenink, Hans Eiskjær, Michiel E. Erasmus	2022	4
5	Detection of NTRK Fusions and TRK Expression and Performance of pan-TRK Immunohistochemistry in Routine Diagnostics: Results from a Nationwide Community-Based Cohort Diagnostics ·r A Nazarchuk PhD Igor L Chereshnyuk PhDp, Chantal C. H. J. Kuijpers, Harry J.M. Groen, Wim Timens, Ed Schuuring, Stefan M. Willems, Léon C.L.T. van Kempen	2022	18
6	AB0659 Recruitment and prevalence of mixed phenotype macrophages is prominent in Bronchoalveolar Lavage (BAL) of Systemic Sclerosis (SSc) patients with Interstitial Lung Disease (ILD). \| Annals of the Rheumatic Diseases Annals of the Rheumatic Diseases ·吴云荣, Touna Mama, Nina Nordström, Yanxi Liang, А.С. Середа, M. van der Leij, 脩造鈴木, M. A. (Murodova) Bakhtiorovna, Wim Timens, Janette K. Burgess, امیر عمرانی, 茂大町, Qiuyue Jiang	2022	0
7	Dynamic Changes of Circulating Tumor DNA Predict Clinical Outcome in Patients With Advanced Non–Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors JCO Precision Oncology ·Sabrina Weber, Paul van der Leest, Cicih Widianingsih, Thomas Schlange, Wim Timens, Menno Tamminga, 紘毅高島, Ricarda Graf, Tina Moser, 水野勉, Marie‐Laure Yaspo, Leon W.M.M. Terstappen, Grigory Sidorenkov, T. Jeroen N. Hiltermann, Michael R. Speicher, Ed Schuuring, Ellen Heitzer, Harry J.M. Groen	2021	45
8	Circulating tumor DNA as a biomarker for monitoring early treatment responses of patients with advanced lung adenocarcinoma receiving immune checkpoint inhibitors Molecular Oncology ·Paul van der Leest, Birgitta I. Hiddinga, Лебедева Татьяна Георгиевна, Владимиров Денис Михайлович, George O'Dell Frie, Arja ter Elst, Wim Timens, Harry J.M. Groen, Léon C.L.T. van Kempen, T. Jeroen N. Hiltermann, Ed Schuuring	2021	23
9	An All-In-One Transcriptome-Based Assay to Identify Therapy-Guiding Genomic Aberrations in Nonsmall Cell Lung Cancer Patients Cancers ·高木信介, Anna A. Rybczynska, 慶子北里, Martijn Terpstra, Ali Saber, Gu Jia-Yao, Wim Timens, Ed Schuuring, T. Jeroen N. Hiltermann, Harry J.M. Groen, Anthonie J. van der Wekken, Anke van den Berg, Klaas Kok	2020	9
10	Immune microenvironment composition in non‐small cell lung cancer and its association with survival Clinical & Translational Immunology ·Menno Tamminga, T. Jeroen N. Hiltermann, Ed Schuuring, Wim Timens, Rudolf S.N. Fehrmann, Harry J.M. Groen	2020	126
11	Genetic regulation of gene expression of MIF family members in lung tissue Scientific Reports ·G. Goldner, Corry‐Anke Brandsma, Maaike de Vries, Wim Timens, Luciana Souza Caminha, Cornelis J. Vermeulen, Maarten van den Berge, Ma’en Obeidat, Philippe Joubert, David C. Nickle, Gerrit J. Poelarends, Alen Faiz, Barbro N. Melgert	2020	10
12	Analysis of Released Circulating Tumor Cells During Surgery for Non-Small Cell Lung Cancer Clinical Cancer Research ·Menno Tamminga, Sanne de Wit, Caroline Van De Wauwer, Hilda van den Bos, Joost F. Swennenhuis, Theo J. Klinkenberg, T. Jeroen N. Hiltermann, Kiki Andree, Diana C.J. Spierings, Peter M. Lansdorp, Anke van den Berg, Wim Timens, Leon W.M.M. Terstappen, Harry J.M. Groen	2019	29
13	CX Chemokine Receptor 7 Contributes to Survival of KRAS-Mutant Non-Small Cell Lung Cancer upon Loss of Epidermal Growth Factor Receptor Cancers ·Bin Liu, Shanshan Song, Rita Setroikromo, Siwei Chen, Shetty Akshar, Deng Chen, Anthonie J. van der Wekken, Barbro N. Melgert, Wim Timens, Anke van den Berg, Ali Saber, Hidde J. Haisma	2019	16
14	Dichotomous ALK-IHC Is a Better Predictor for ALK Inhibition Outcome than Traditional ALK-FISH in Advanced Non–Small Cell Lung Cancer Clinical Cancer Research ·Anthonie J. van der Wekken, P. Hubber, Stephan Neuhäuser, 橋本和宣, M F Mastik, Lizza Hendriks, Erik H.F.M. van der Heijden, Monika Looijen-Salamon, Adrianus J. de Langen, Hui Feng, Sietske A. Riemersma, B.E. van den Borne, Ernst‐Jan M. Speel, Anne‐Marie C. Dingemans, T. Jeroen N. Hiltermann, Anke van den Berg, Wim Timens, Ed Schuuring, Harry J.M. Groen	2017	51
15	A Potent Tartrate Resistant Acid Phosphatase Inhibitor to Study the Function of TRAP in Alveolar Macrophages Scientific Reports ·Carian E. Boorsma, A. van der Veen, Ian Alvarado-Vélez, Andreia de Almeida, Christina Draijer, Thaís Mauad, György Fejér, Corry‐Anke Brandsma, Maarten van den Berge, Yohan Bossé, Don D. Sin, Ke Hao, Anja Reithmeier, Göran Andersson, Peter Olinga, Wim Timens, Angela Casini, Barbro N. Melgert	2017	20
16	Prostaglandin E ₂ promotes MYCN non‐amplified neuroblastoma cell survival via β‐catenin stabilization Journal of Cellular and Molecular Medicine ·Т.А. Савватеева, Fillah Muty Syahidah, Muhammad Fadil Pramudiansyah, I El-Khantoury, Carolina R.S. Elzinga, Wim Timens, Reinoud Gosens, Eveline S. de Bont, Martina Schmidt	2014	20
17	Inhaled Steroids Modulate Extracellular Matrix Composition in Bronchial Biopsies of COPD Patients: A Randomized, Controlled Trial PLoS ONE ·Lisette I.Z. Kunz, Hemalatha Beesetti, G Martin, Thérèse Lapperre, Peter J. Sterk, Dirkje S. Postma, Thaís Mauad, Wim Timens, Pieter S. Hiemstra, (unknown)	2013	72
18	Molecular Signature of Smoking in Human Lung Tissues Cancer Research ·Yohan Bossé, Dirkje S. Postma, Don D. Sin, Maxime Lamontagne, Christian Couture, Nathalie Gaudreault, Philippe Joubert, Vivien W. Wong, Mark Elliott, Maarten van den Berge, Corry‐Anke Brandsma, Catherine Tribouley, Vladislav A. Malkov, Jeffrey A. Tsou, Gregory J. Opiteck, James C. Hogg, Andrew J. Sandford, Wim Timens, Peter D. Paré, Michel Laviolette	2012	93
19	Transforming growth factor beta-1 gene polymorphisms and course of asthma European Respiratory Journal ·Despo Ierodiakonou, Dirkje S. Postma, Gerard H. Koppelman, Jorrit Gerritsen, Wim Timens, H. Marike Boezen, Judith M. Vonk	2011	1
20	Phosphodiesterase 4 Inhibitors American Journal of Respiratory and Critical Care Medicine ·Huib A.M. Kerstjens, Wim Timens	2003	5

About Wim Timens

Wim Timens is a scholar working on Pulmonary and Respiratory Medicine, Physiology, Immunology, Emergency Medical Services and Cancer Research, having authored 458 papers that have together received 20.3k indexed citations. Recurring topics across this work include Chronic Obstructive Pulmonary Disease (COPD) Research (110 papers), Asthma and respiratory diseases (104 papers), Neonatal Respiratory Health Research (62 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (37 papers), Lung Cancer Treatments and Mutations (31 papers), Respiratory and Cough-Related Research (26 papers), Pediatric health and respiratory diseases (23 papers) and Cancer-related molecular mechanisms research (22 papers). The work is most often cited by research in Infectious Diseases (4.2k citations), Pulmonary and Respiratory Medicine (7.2k citations), Physiology (4.2k citations), Immunology (3.2k citations) and Neurology (2.3k citations). Wim Timens has collaborated with scholars based in Netherlands, United States and Canada. Frequent co-authors include Harry van Goor, Dirkje S. Postma, G. Navis, Inge Hamming, A. Titia Lely, James C. Hogg, Machteld N. Hylkema, Corry‐Anke Brandsma, Harry J.M. Groen and Nick H.T. ten Hacken. Their work appears in journals such as European Respiratory Journal, PLoS ONE, Respiratory Research, American Journal of Physiology-Lung Cellular and Molecular Physiology and Thorax.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact